Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. Oktober 2023 08:15 ET | Quelle: Panbela Therapeutics, Inc.

Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
25. Oktober 2023 08:15 ET | Quelle: Panbela Therapeutics, Inc.

Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication

MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
24. Oktober 2023 08:15 ET | Quelle: Panbela Therapeutics, Inc.

Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023

MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
26. September 2023 08:15 ET | Quelle: Panbela Therapeutics, Inc.

Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical...
19. September 2023 08:15 ET | Quelle: Panbela Therapeutics, Inc.

Panbela to Present at the LD Micro Investor Conference

MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
05. September 2023 08:15 ET | Quelle: Panbela Therapeutics, Inc.

Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi

MINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
28. August 2023 08:15 ET | Quelle: Panbela Therapeutics, Inc.

Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference

MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
14. August 2023 08:15 ET | Quelle: Panbela Therapeutics, Inc.

Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
10. August 2023 16:10 ET | Quelle: Panbela Therapeutics, Inc.

Panbela Provides Business Update and Reports Q2 2023 Financial Results

MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
31. Juli 2023 16:15 ET | Quelle: Panbela Therapeutics, Inc.

Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023

MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...

Vorherige Seite

Nächste Seite